A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis
← catalyst calendarNCT07533955 · readout ≤ 437 d
Sponsored by Jade Biosciences, Inc. (industry) · JBIO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
36estimated
Sites
3
Countries
Moldova, Ukraine
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-19 | actual | When the study began enrolling |
| Primary completion | Oct 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rhematoid Arthritis
Interventions
- Drug: JADE201
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFSafety and Tolerability of Single Ascending Doses of JADE201 in participants with Rheumatoid Arthritis
measured Day 1 through 36 weeks
Permalink · JBIO's whole pipeline · Catalyst calendar · Every registered study · What changed